Blair William & Co. IL Has $231,000 Holdings in Tempus AI, Inc. (NASDAQ:TEM)

Blair William & Co. IL lessened its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 48.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,839 shares of the company’s stock after selling 6,475 shares during the quarter. Blair William & Co. IL’s holdings in Tempus AI were worth $231,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Kovitz Investment Group Partners LLC bought a new position in shares of Tempus AI during the third quarter valued at $1,367,000. Victory Capital Management Inc. acquired a new stake in shares of Tempus AI in the 4th quarter worth about $216,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Tempus AI in the fourth quarter valued at approximately $1,091,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Tempus AI during the 4th quarter valued at $178,000. Finally, abrdn plc bought a new position in shares of Tempus AI during the fourth quarter valued at about $2,784,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Insider Activity

In related news, EVP Andrew Polovin sold 13,135 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $45.98, for a total transaction of $603,947.30. Following the transaction, the executive vice president now directly owns 154,171 shares of the company’s stock, valued at approximately $7,088,782.58. This trade represents a 7.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Wayne A.I. Frederick sold 3,000 shares of the company’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $45.54, for a total transaction of $136,620.00. Following the completion of the sale, the director now directly owns 26,514 shares of the company’s stock, valued at $1,207,447.56. This trade represents a 10.16 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,601,969 shares of company stock worth $317,330,782.

Tempus AI Stock Down 7.8 %

Tempus AI stock opened at $42.58 on Friday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The business has a 50-day simple moving average of $58.27 and a 200 day simple moving average of $51.45. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $91.45.

Analysts Set New Price Targets

A number of research firms have recently commented on TEM. Needham & Company LLC lifted their target price on Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Guggenheim reissued a “buy” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Bank of America upped their price target on Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. downgraded shares of Tempus AI from an “overweight” rating to a “neutral” rating and lifted their target price for the stock from $50.00 to $55.00 in a research note on Tuesday, February 25th. Finally, Loop Capital lowered their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.18.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.